Brokers Issue Forecasts for Iovance Biotherapeutics, Inc.'s FY2026 Earnings (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Analysts at Zacks Research issued their FY2026 earnings per share estimates for Iovance Biotherapeutics in a research note issued on Wednesday, March 20th. Zacks Research analyst S. Ganoria expects that the biotechnology company will post earnings per share of ($1.03) for the year. The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.41) per share.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $1.44 million. During the same period last year, the firm posted ($0.64) earnings per share.

A number of other brokerages have also recently issued reports on IOVA. StockNews.com upgraded shares of Iovance Biotherapeutics to a "sell" rating in a report on Friday, February 2nd. JMP Securities boosted their target price on Iovance Biotherapeutics from $18.00 to $25.00 and gave the stock a "market outperform" rating in a report on Tuesday, February 20th. Wells Fargo & Company lifted their target price on shares of Iovance Biotherapeutics from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, March 1st. HC Wainwright restated a "buy" rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 29th. Finally, Barclays lifted their price objective on Iovance Biotherapeutics from $18.00 to $22.00 and gave the stock an "overweight" rating in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $24.64.

Iovance Biotherapeutics Stock Up 2.9 %

IOVA stock traded up $0.43 during trading hours on Thursday, hitting $15.36. The company's stock had a trading volume of 7,288,482 shares, compared to its average volume of 10,252,955. The stock has a 50 day moving average price of $11.58 and a two-hundred day moving average price of $7.68. Iovance Biotherapeutics has a 12 month low of $3.21 and a 12 month high of $18.33. The company has a market capitalization of $4.29 billion, a PE ratio of -8.42 and a beta of 0.63.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IOVA. Vanguard Group Inc. grew its stake in Iovance Biotherapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 22,812,820 shares of the biotechnology company's stock valued at $185,468,000 after acquiring an additional 669,350 shares during the period. BlackRock Inc. grew its holdings in shares of Iovance Biotherapeutics by 36.5% during the second quarter. BlackRock Inc. now owns 17,001,791 shares of the biotechnology company's stock worth $119,693,000 after buying an additional 4,545,129 shares in the last quarter. Perceptive Advisors LLC raised its position in Iovance Biotherapeutics by 53.8% in the 1st quarter. Perceptive Advisors LLC now owns 15,339,735 shares of the biotechnology company's stock valued at $93,726,000 after buying an additional 5,367,955 shares during the last quarter. MHR Fund Management LLC acquired a new position in Iovance Biotherapeutics during the 4th quarter worth approximately $76,661,000. Finally, State Street Corp grew its stake in shares of Iovance Biotherapeutics by 71.9% during the 2nd quarter. State Street Corp now owns 11,770,751 shares of the biotechnology company's stock worth $129,949,000 after acquiring an additional 4,925,025 shares in the last quarter. Institutional investors own 81.85% of the company's stock.

Insider Buying and Selling

In related news, Director Merrill A. Mcpeak acquired 250,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was purchased at an average price of $9.15 per share, for a total transaction of $2,287,500.00. Following the transaction, the director now owns 320,150 shares of the company's stock, valued at approximately $2,929,372.50. The acquisition was disclosed in a filing with the SEC, which is available through this link. 10.40% of the stock is owned by corporate insiders.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.